MRG006A

Phase 2Small molecule

LLepu Biopharma Co., Ltd.

MRG006A is one of 72 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaRecruiting

Patients With Advanced Solid TumorsRecruiting

Hepatocellular CarcinomaPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Sovaldi

Gilead

Preclinical

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Hepsera

Gilead

Preclinical

—5

MRG006A

LLepu Biopharma Co., Ltd.

Phase 2

1 6

Doptelet

AAkarx

Preclinical

1 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

Vermox

WWim Janssens

Preclinical

1 9

Valemetostat

Bristol-Myers Squibb

Preclinical

1 10

Alcohol

Astellas

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT07093970

Q2 2029

PreclinicalRecruiting

Hepatocellular Carcinoma

NCT07479485

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

Recruiting·LLepu Biopharma Co., Ltd.·Phase 1/2·NCT07093970·343 enrolled

Hepatocellular Carcinoma1 trial

An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

Recruiting·LLepu Biopharma Co., Ltd.·Preclinical·NCT07479485·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MRG006A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MRG006A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MRG006A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lepu Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLepu Biopharma Co., Ltd.

MRG006A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News